October 23, 2024 11:26 AM EDT
News Briefing

Ec­co­gene gets $60M from As­traZeneca; Evotec al­so records mile­stone with BMS

ENDPOINTS

Plus, news about DBV, Dou­ble Point Ven­tures and Lu­mos:

Ec­co­gene’s $60M mile­stone from As­traZeneca: The pay­ment ar­rived af­ter Ec­co­gene met sev­er­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Mer­ck pays $30M to buy ‘chameleon’ ap­proach to dead­ly brain can­cers

Eye drop mak­er to merge with a reti­nal gene ther­a­py start­up from Spark co-founder

Al­to Neu­ro­science's mid-stage tri­al miss­es pri­ma­ry end­point in de­pres­sion

UK’s price watch­dog says Lil­ly’s Alzheimer’s drug is too cost­ly for broad up­take

Ra­dio­phar­ma star­tups stay hot as Al­pha-9 bags $175M Se­ries C

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times